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Subacute cutaneous lupus erythematosus (SCLE) was origi-
nally described and distinguished from discoid lupus ery-th~matosus (OLE) on the basis of clinical examination of the 
shn, but subsequent reports have questioned the concept of 
SCLE as a marker of a unique subset of LE patients. 
We classified 27 lupus patients, on the basis of cutaneous 
exam, as having discoid lupus skin lesions, subacute cutane-
o~s skin lesions, or systemic lupus erythematosus (SLE) 
Without OLE or SCLE lesions. Clinical features most charac-
~eristic of SCLE rather than OLE were supe~fi.cial, fo1on-in-
u~ated, non-scarring lesions, and photosenSitivIty, With lack ff l.nduration being the single most helpful fin~ing. Histo-
oglc examination oflesional skin showed a relatively sparse, 
~perficial infiltrate in SCLE and a denser, deeper infiltrate in 
fl LE. A distinctive pattern of staining with direc~ i.mmuno-
t uores.cence, particulate epidermal IgG depOSitIOn, w~s 
ound In seven of seven SCLE patients (all anti-Ro/SSA POSl-
tive) and none of the other patients. This distinctive pattern 
can be reproduced experimentally when anti-Ro/SSA au-
toantibodies are infused into human skin-grafted mice. Par-
ticulate dermal-epidermal junctional staining was the pattern 
seen in the patients who did not have SCLE. 
Clinically defining SCLE as a superficial inflammatory 
form of cutaneous lupus (i.e., considering lesions to be OLE if 
they are indurated) results in a meaningful segregation of 
SCLE and OLE patient groups. The epidermal IgG deposits 
unique to SCLE provide independent evidence that Fhe clini-
cal findings that were used to identify the patient groups 
actually identify distinctive cutaneous lupus subsets. The ob-
servation that antibodies are present in a different location in 
the skin in SCLE than in OLE indicates that SCLE and OLE 
are likely to have different pathomechanisms.] Invest Derma-
tol 99:251-257, 1992 
---------------------------------------------------------------------------------------------------------
Cutaneous lesions occur in a majority oflupus patients, and constitute four of the 11 American Rheumatism Association (ARA) criteria for the classification of systemic lupus erythematosus (discoid lesions, malar rash, photosensitivity, and oral ulcers) [1]. It has been 
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reported that within the "discoid lesions" group, there are sub-
groups of patients who are distinct with regard to such features as 
their responses to ultraviolet light, the production of scarring skin 
lesions, and the character of their systemic disease. In 1979, Sont-
heimer, Thomas, and Gilliam described 27 patients with histologi-
cally documented cutaneous lupus erythematosus (LE) who had 
unique skin lesions, which they termed subacute cutaneous lupus 
erythematosus (SCLE) [2] . SCLE, which would previously have 
been classified as discoid lupus erythematosus (DLE), occurred 
in 10% of lupus patients and was distinguishable from typical 
DLE on the basis of the absence of scarring, the frequent occur-
rence of photosensitivity, and photodistribution of widespread 
papulosquamous or annular lesions. SCLE patients typically 
had a mild systemic disease, consisting of arthralgias and other 
musculoskeletal complaints, but not renal or central nervous sys-
tem involvement. The majority of patients reported by Sont-
heimer, Thomas, and Gilliam had anti-Ro/SSA antibodies [3] 
and the human histocompatibility antigen HLA-DR3 tissue type 
[4]. A histologic study of cutaneous lesions found that SCLE could 
be distinguished from DLE in 82% of specimens examined [5]. 
Thus, on the basis of clinical findings, serology, immunogenetics, 
histology, and prognosis, SCLE patients constitute a distinct subset 
ofLE. 
Despite these data, describing SCLE as a distinct, relatively homo-
geneous subset oflupus, other investigators have not found homoge-
neity in .their SCLE patient group. Some observers have reported 
that clIl1lcal features are vanable [6,7] , that SCLE is indistinguish-
able 11Istologlcally from DLE [8 ,9], and that a minority of SCLE 
patients have anti-Ro/SSA antibodies [6 ,7,10-12]. These disparate 
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results raise the possibility that the clinical classification of cutane-
ous lupus patients differs from one institution to another. The over-
all effect of these reports is to question the concept of SCLE as a 
cutaneous marker of a distinctive subset of LE. 
Defining SCLE in a consistent way also has implications con-
cerning research into the pathogenesis of lupus. Although lupus 
erythematosus is strongly associated with autoantibodies, cutaneous 
lupus has been cited as evidence against the involvement of antibod-
ies in the disease process. DLE lesions have been reported to develop 
prior to the deposition of antibodies in the skin [13]. Further, many 
D LE patients do not have detectable circulating autoantibodies [14]. 
The discovery of SCLE has led to a re-examination of the role of 
autoantibodies in lupus . First, SCLE, as described by Sontheimer et 
ai, is strongly associated with anti-Ro/SSA autoantibodies [3] . Sec-
ond, anti-Ro/SSA antibodies have been shown to deposit in the skin 
in a distinctive particulate pattern in the epidermis in an experimen-
tal model [15 ,16]. Third, SCLE lesions can occur in the offspring of 
women with anti-Ro/SSA antibodies, suggesting that placental 
transmission of the autoantibodies leads to disease [17,18]. In this 
disease, termed neonatal lupus erythematosus (NLE), the cutaneous 
lesions are transient and have a time course that parallels that of 
maternally derived IgG antibodies. 
Investigators have used antibodies from SCLE patients to exam-
ine Ro/SSA [19-23]. Techniques using lupus antisera have 
previously been used to determine the functions of the RNA bind-
ing proteins Sm, UIRNP, and La/SSB [24-26]. Sm and UIRNP are 
involved in splicing hnRNA [27,28] and La/SSB is a transcription 
termination factor for RNA polymerase III [29]. Like Sm, U1RNP, 
and La/SSB, the 60-kD Ro/SSA protein binds RNA, but its func-
tion is not known [30]. SCLE and DLE patients have also been 
subjects of studies to determine the effects of ultraviolet light in 
lupus [31,32] .. It is essential for the application of the above infor-
mation to clinical practice that SCLE and DLE groups be distin-
guished appropriately. 
The purposes of the present study were as follows: 1) to re-evalu-
ate the hypothesis that SCLE is a distinct lupus subset; 2) to identify 
clinical findings most helpful in distinguishing SCLE from DLE; 3) 
to identify histologic findings helpful in distinguishing SCLE from 
DLE; 4) to evaluate the hypothesis that epidermal IgG deposition is 
a diagnostic marker ofSCLE; and 5) to examine the hypothesis that 
SCLE and DLE have different pathogeneses. 
MATERIALS AND METHODS 
Patients were selected on the basis of cutaneous examination. In 
classifying the skin disease, criteria reported by Sontheimer and 
Gilliam were used [14]. In addition, one of the authors (KD-B) had 
previously participated in a study of 47 SCLE patients followed by 
Sontheimer and Gilliam [33] . Thus, past clinical experience in ex-
amining some of the originally described group of SCLE patients as 
well as reference to the published descriptions ofSCLE were used to 
assist in diagnosis. Serologies (i.e., anti-Ro/SSA antibodies), histol-
ogy, and immunofluorescence were not used to assist in the clinical 
classification of the skin lesions. At least two of the authors evalu-
ated each patient (KD-B, SB, LL) . Based on examination of skin 
lesions, patients were classified as having DLE, SCLE, or neither 
D LE nor SCLE. The 1982 revised criteria for the classification of 
SLE were used to classify patients as having SLE [1]. Thus, three 
major categories of patients were identified: 1) DLE patients (with 
or without SLE), 2) SCLE patients (with or without SLE), and 3) 
SLE patients without DLE or SCLE lesions (see Table I). 
Lesions of DLE and SCLE, of at least 1 month's duration, were 
obtained for histopathologic examination. Early, active lesions were 
preferred for biopsy for two reasons. First, the presence of scarring 
in an older lesion would bias the examiner toward the diagnosis of 
DLE. Second, a purpose of this study was to identify histologic 
features that can aid in distinguishing DLE from SCLE. Thus, it is 
much more relevant to compare early, inflammatory lesions ofDLE 
with inflammatory SCLE lesions than to compare scarred lesions of 
well-established DLE with inflammatory lesions of SCLE. Speci-
mens processed for standard histopathologic examination were sub-
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Table I. Clinical Features of Study Patients 
Mean Sex Race 
Number Age (P/M) (W/B/H)' 
DLE patients 11 48 5/6 8/3/0 
Systemic disease 6 
No systemic disease 5 
SCLE patients 7 54 5/2 7/0/0 
Systemic disease 2 
No systemic disease 5 
SLE patients (without 9 42 8/1 7/1/1 
DLE or SCLE lesions) 
'W. white; B. black; H. hispanic. 
mitted without clinical history to two dermatopathologists for in?e-
pendent review. In addition, each of three dermatologIstS 
independently reviewed the slides without knowledge of the pa-
tient's name or diagnosis. Each specimen was scored for the presence 
or absence of the histologic features delineated previously by Ban-
gert, Freeman, Sontheimer, and Gilliam [5] . These included hyper-
keratosis; parakeratosis; acanthosis; epidermal and pilosebaceous at-
rophy; edema; colloid bodies; liquefaction; basement-memb~ane 
thickening; dermal melanosis; follicular plugging; type, 10catlOnd 
and density of the inflammatory infiltrate; vascular changes; a? 
myxoid degeneration. Each feature was graded 0 to 4+, or ~eslg­
nated as " - " if the feature could not be graded. For example, If the 
sections lacked pilosebaceous structures, follicular plugging could 
not be evaluated. Additionally, using the criteria of Bangert et ai, a 
histologic diagnosis (DLE or SCLE) was rendered by each exam-
iner. After all biopsies were reviewed, the clinical diagnoses were 
provided, and the grading for each histologic feature as well as the 
overall diagnostic impression was evaluated with discriminant anal( 
ysis. In addition, the results were analyzed by grouping ratings 0] 
0-2+ versus 3-4+, as was done in the study by Bangert et al [5. 
The ratings of the five observers were averaged and compared for 
DLE and SCLE, using chi squares with Fisher's exact test. 
All subjects, including those without cutaneous lesions, had evalU-
ation of immunoreactants in skin using direct immunofluorescenc)e 
(DIF) . Biopsies were examined from lesional skin (DLE and SCLE , 
non-Iesional sun-exposed skin of the dorsal forearm (all pat~ents)), 
and non-lesional sun-protected skin of the buttock (all patients . 
Briefly, tissues were immediately frozen in liquid nitrogen, t~e~ 
mounted in OCT (Tissue Tek, Naperville, IL). Four-micron- thlc 
sections were cut and stored at -70°C until used. Prior to incuba-
tion with the conjugates, slides were dipped briefly in phosphate-
buffered saline (PBS), pH = 7.2, to remove the OCT. Slides we~e 
incubated at room temperature for 1-2 h in fluorescel:; 
isothiocyanate-conjugated rabbit anti-human IgG, IgA, IgM, a~O 
C3b (Cappel, Durham, North Carolina), each at a dilutionof1 : 2 I 
in PBS. After incubation the slides were washed in PBS with gent e 
rocking for 10 min, and then placed briefly in deionized water 
followed by a brief exposure to 100% acetone at 4 ° C. Slides were aIr 
dried, then covered with glycerol mounting medium with parad phenylenediamine (PPD) [34]' and examined immediately or store d 
in the dark at 4 ° C and viewed within 72 h. All slides were revleWe. 
by two of the authors (KD-B, LL). Fluorescent staining of the epld dermis, dermal-epidermal junction, and dermis was evaluated, a.n _ 
the pattern of staining was noted. In addition, the intensity of stal~l 
ing in lesional versus non-Iesional sun-exposed versus non~l esloni_ 
sun-protected sites was compared. D IF examination of 10 skIn s£eces 
mens from patients undergoing elective plastic surgical proCe ur i-
was done using methods identical to our study patients. These spec 
mens served as our controls. d-
Each patient underwent serologic testing, with antinuclear an ld 
bodies (ANA) performed on Hep-2 cells, and anti-Ro/SSA alo_ 
anti-La/SSB antibodies determined by Ouchterlony l1nmu~e_ 
diffusion, using Wil-2 extract and rabbit thymus extract as the ri-
spective antigens. Three DLE sera previously reported to be an 
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Figure 1. Scarring plaques of DLE on the face and lower lip. 
~O/SSA posItive were retested uSlllg an Ouchterlony with calf 
:. YlUus extract as the antigen source, and with an enzyme-
Inked immunosorbent assay (ELISA) for antibodies to 60-kD 
RalSSAI [35,36]. 
RESULTS 
Cl' , . d 
. Inlcal Assessment A total of 27 patients were categorIze cl~nlcally, including 11 with discoid LE lesions (see Fig 1), seven 
~lth SCLE lesions (see Fig 2), and nine SLE patien~s wi~h neither 
LE nor SCLE lesions. Demographic data is summanzed III Table I. 
Of the patients with DLE or SCLE, four presented de novO to the 
Figure 2. Scaly, pink, thin plaques of SCLE in a photodistribution. 
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authors, and 14 were referred by other physicians. The nine SLE 
patients were randomly selected from the lupus clinic populations 
of the rheumatology divisions at our institutions. The majority of 
DLE patients in this study were male, whereas all but one SLE 
patient were female. Two of seven SCLE patients were male. All of 
the SCLE patients were Caucasian, not a surprising finding as SCLE 
has been reported predominantly in Caucasians. 
In all cases, the authors were in agreement regarding the clinical 
diagnosis. Induration of lesions was the single most important fea-
ture indicative of DLE (present in 11 of 11 DLE and zero of seven 
SCLE patients). Other helpful features included the following: pres-
ence of lesions on the face (11 of 11 DLE, one of seven SCLE), or 
scalp (eight of 11 DLE, one of seven SCLE); scarring (10 of 11 DLE, 
zero of seven SCLE); exacerbation or initiation of eruption after sun 
exposure (two of 11 DLE, six of seven SCLE); photodistributed 
eruption (one of 11 DLE, six of seven SCLE); and relatively sym-
metric distribution of lesions (four of 11 DLE, seven of seven 
SCLE). 
In three of 14 cases referred for this study, the authors' diagnoses 
differed from that of the referring physician. These were patients 
with extensive, photodistributed DLE (see Fig 3A,B), and DLE 
patients with anti-RojSSA antibodies. 
In addition to cutaneous examination, each patient was evaluated 
for presence of the ARA 1982 revised criteria for the classification of 
SLE [1] . As indicated in Table I, six of 11 DLE patients met four or 
more criteria, as did two of seven SCLE patients. All of the patients 
classified as SLE without discoid or subacute cutaneous LE lesions 
met four or more ARA criteria by definition. 
Pathologic Assessment A total of 17 biopsies from 17 patients 
were evaluated by two dermatopathologists and three dermatolo-
gists independently. Overall, the pathologic diagnosis agreed with 
the clinical diagnosis in an average of 15.4 of the 17 specimens. 
All of the evaluators agreed in 12 of 17 biopsies. The 12 biopsies 
in which all evaluators agreed generally had classic histologic find-
ings ofDLE (hyperkeratosis, follicular plugging, adnexal infiltrates, 
deep perivascular infiltrates) or SCLE (a predominantly superficial, 
sparser infiltrate without prominent adnexal involvement), and the 
evaluators had a high degree of confidence in the histologic diagno-
sis (see Fig 4A,B). When the degree of confidence in the histologic 
diagnosis was high (in seven of 10 DLE and five of seven SCLE 
biopsies), the histologic diagnosis concurred with the clinical diag-
nosis in 100%. The remaining biopsies (five of 17) had features 
intermediate between DLE and SCLE. Those features most helpful 
in making the distinction between DLE and SCLE were the depth 
and intensity of the dermal inflammation and the degree of hyper-
keratosis. A higher score for each of these factors correlated with a 
clinical diagnosis of DLE, with lower scores associated with SCLE. 
Using these criteria, histologic discrimination between DLE and 
SCLE was possible in 84% of specimens, with discriminant analysis 
showing two-tailed significance at the 0.001 level. The results for 
the averaged scores, when compared as in Bangert's study [5], in 
groups of 0 - 2+ versus 3 - 4+ were similar, with the presence of a 
deep perivascular infiltrate, and hyperkeratosis correlating signifi-
cantly with DLE, at a p < 0.01 level. 
Serologic Assessment All of our study patients had ANA at a 
titer considered to be positive, except for three DLE patients with-
out systemic disease. All seven of our SCLE patients had anti-Roj 
SSA antibodies, with one patient having anti-LajSSB antibodies in 
addition. Three of the DLE patients, two of whom had systemic 
disease, had previously been reported to have anti-RojSSA antibod-
ies. Sera from these patients, drawn at or near the time of evaluation 
in this study, were retested for antibodies to RojSSA. None of the 
sera had anti-RojSSA precipitin lines on repeat examination in 
Ouchterlony using calf thymus extract as the antigen source. How-
ever, two of the sera had anti-RojSSA antibodies in an ELISA. The 
antibody binding detected in the ELISA was of a lower level than is 
usual for anti-RojSSA- positive patients, but was completely inhib-
ited by purified 60-kD Ro/SSA antigen. The patient who was nega-
tive for anti-RojSSA on repeat examination had severe systemic 
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A 
B 
Figure 3. OLE lesions occurring in a photodistribution. A. Generalized 
OLE, with lesions on the dorsal arms, forearms, and hands. Lesions were also 
present on the face. B. Close inspection of individual lesions reveals scarring, 
atrophy, and follicular plugging. 
disease and had been treated with immunosuppressive agents. The 
number of anti-Ro/SSA antibody positive patients in the DLE 
group may reflect a bias for referring these patients to our institu-
tion. Two of these three anti-Ro/SSA antibody positive DLE pa-
tients were referred as SCLE patients, but on examination had DLE 
lesions instead. 
Direct Immunofluorescence Assessments 
Lesional Skin Findings: Eight of 11 DLE patients and all of the 
SCLE patients had staining with IgG andlor IgM in lesional skin 
biopsies. The pattern of staining, however, was strikingly different 
in these two diseases (Fig 5). In DLE patients, the pattern was always 
particulate staining at the dermal-epidermal junction (DE]), a pat-
tern consistent with what many have termed the lupus band pattern 
(Fig 6A). Two of 11 patients had IgG deposited at the DE], four of 
11 had IgA, eight of 11 had IgM, and 11 of 11 had C3b staining at 
the DE]. In SCLE patients, the IgG pattern was a particulate epider-
mal staining (Fig 6B). This pattern was observed in all lesional 
specimens. IgA was not found in any SCLE lesional specimens. IgM 
staining, present in seven of seven lesional biopsies, was found at the 
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A 
B 
Figure 4. Cutaneous histology of OLE and SCLE. A. Biopsy from a DLE 
lesion, with hyperkeratosis, follicular plugging, and a superficial and dec.p 
mononuclear inflammatory cell infiltrate. (Hematoxylin and Eosin, magnI-
fication X 31 .2.) B. Biopsy of a SCLE lesion, showing a more sparse, supcr-
ficial infiltrate. (Hematoxylin and Eosin, magnification X 31.2.) 
DE], but was more extensive than that seen in DLE, with stai~ing 
found in the lower epidermis and upper dermis in SCLE lesiOns. 
C3b staining at the DE] was found in five of seven specirnelld When comparing DIF findings in lesional skin of both DLE all 
SCLE patients, there were no significant differences betweell the 
findings in patients with systemic disease versus those without sys-
temic disease. 
Non-Lesional Skin Findings For DLE patients, IgG and C.3~ 
deposition in uninvolved skin was found only in those patients Wltj\ 
systemic disease. One DLE patient without systemic disease had IgM in non-lesional sun-exposed skin (dorsal forearm), and one ha? Ig 
in non-Iesional sun-exposed skin; however, no DLE patient WIthout 
systemic disease had any immunoreactants in non-lesional unex-
posed skin (buttock). These findings are consistent with prior ~e: 
ports of the correlation of immunoreactants at the DE] in non- e 
sional skin of DLE patients with systemic disease. 
In SCLE patients, the findings were quite different. All of .rh.ese 
patients had IgG (particulate epidermal staining) and IgM (staJUJUg 
at the DE], and extending into the lower epidermis and uPbe~ 
dermis) in non-lesional sun-exposed skin, all had IgG, and all .~ 
one had IgM in non-lesional unexposed skin as well. The int~nSI I 
of staining with IgG was not appreciably different when leslon~ ~ 
non-lesional sun-exposed, and non-lesional unexposed skin biOPSle 
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ERYTHEMATOSUS 
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Figure 5. DIF pattern comparisons in DLE, SCLE, and SLE. Immunoreac-
tants are depicted by small black dots. For IgG, deposition was at the DE) for D~E and SLE. In contrast, SCLE patients had IgG deposition throughout the 
e~ldermis . For IgM and C3b, the patterns of deposition were similar, except A 
t at the band was broader in SCLE patients. 
Were compared. None of the SCLE patients had IgA in non-lesional S~IIl, and three had C3b in non-lesional skin. Among SCLE pa-
tl~nts, there was no difference in presence or pattern of staining 
With any of the immunoreactants, when comparing those patients 
WI~h and without systemic disease. Thus, unlike DLE, the presence 
of I.rnrnunoreactants in non-lesional skin of SCLE patients was not 
an IIldication of systemic disease. 
b In SLE patients, IgM was the immunoreactant most commonly 
ound, present at the DE] in seven of nine patients, in both sun-ex-
pOsed and unexposed skin. IgG was present in one of nine patients in 
sun-exposed skin and in two of nine biopsies of unexposed skin. IgA 
Was found in one patient, in both sun-exposed and unexposed skin. 
C3b. Was present in three of nine specimens from sun-exposed skin 
and .1Il two of nine from unexposed skin. The immunofluorescence ~ndlllgs for IgG andlor IgM in all patient groups are summarized in 
1 able II. 
DISCUSSION 
(ontheimer and Gilliam identified and described a unique subset of 
upus patients, characterized by a specific cutaneous eruEtion, sub-
~~ute Cutaneous lupus erythematosus. SCLE patients differed from 
d' E patients as a whole, in that renal and central nervous system 
Isease were less frequently observed in SCLE. A 1 O-year follow-up 
Study of SCLE patients documented a decreased mortality in SCLE 
patients as compared to unselected SLE patients [33] . With regard to 
CUtaneous lesions, SCLE differed from DLE in that scarring was 
unUsual in SCLE, and SCLE lesions were more likely to be initiated 
Or exacerbated by ultraviolet light exposure. Their later studies, 
Including histologic exam, serologic tests for anti-Ro/SSA antibod-~~ an~ HLA antigen determinations, supported the hypothesis that 
b LE IS a distinctive subset of lupus. In subsequent studies' of SCLE 
. Yother investigators, the clinical, histologic, and serologic find-fin~s have not been as consistent. Thus, it seems that patients classi-
th as having SCLE at different institutions are not the same as 
Ose lUitially described by Gilliam and Sontheimer. One possible e~planation for this would be that different investigators' diagnostic 
Ctlteria for SCLE are not uniform. 
of We have identified several potential pitfalls in the classification 
v CUtaneous LE. One problem encountered is the D LE patient with 
s ery early or with treated skin lesions. These patients may not have S~Zlllg or follicular plugging and thus this may be confused with 
C E. However, even very early lesions ofDLE are indurated, and 
an be COntrasted with SCLE lesions, which usually lack induration. 
B 
Figure 6. Immunofluorescence findings in DLE and SCLE. A. DIF exam of 
a lesion ofDLE shows particulate deposition ofIgG at the dermal-epidermal 
junction. (FITC IgG, magnification X 250.) B. Direct immunofluorescence 
exam of a lesion of SCLE shows particulate deposition of IgG throughout 
the epidermis. T he DE) is marked with arrolVS. (FITC IgG, magnification 
X250.) 
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Table II. Summary of DIF Findings in Study Patients 
IgG andlor IgM 
n Lesional Forearm Buttock 
DLE 11 8 4 4' 
Systemic disease 6 4 3 4 
No systemic disease 5 4 1 0 
SCLE 7 7 7 7 
Systemic disease 2 2 2 2 
No systemic disease 5 5 5 5 
SLE 9 7 7 
• One OLE patient did not have OIF performed on buttock skin. 
A second problem is that some patients with SCLE have limited 
disease. Because SCLE lesions have typically been described as exten-
sive, the paucity oflesions might suggest DLE; however, the super-
ficial nature of these lesions should distinguish them. Third, pa-
tients with the generalized form ofDLE may have photodistributed 
lesions, and this might be confused with SCLE on the basis oflesion 
distribution. In addition to finding scarring and follicu lar plugging, 
induration oflesions supports a diagnosis of generalized DLE rather 
than SCLE. Last, DLE patients with anti-Ro/SSA antibodies may be 
mistaken for SCLE, as was the case in two of the patients referred to 
us. Although serologies were not used in the initial identification of 
SCLE [2], and Sontheimer has recently emphasized that the diagno-
sis of SCLE is not limited to those patients who produce anti-Rol 
SSA antibodies [37]. it is possible that some clinicians use the pres-
ence of anti-Ro/SSA antibodies to establish a diagnosis of SCLE or 
exclude a diagnosis of DLE. 
The most useful characteristic of SCLE that distinguishes it from 
DLE in the above situations is that it is a superficial (i.e., not indu-
rated and not scarring) inflammatory disease. In retrospect, it seems 
reasonable to presume that the original group of SCLE patients 
described by Gilliam and Sontheimer had lesions characterized by a 
lack of induration, because of their histologic findings: that the 
inflammation in SCLE lesions was sparse and superficial in compari-
son to the denser, deeper inflammation found in DLE lesions. In a 
histologic study by other investigators, a deeper inflammatory infil-
trate was reported in SCLE, suggesting that many of their SCLE 
patients had indurated lesions [9]. Thus, including patients with 
indurated lesions in the SCLE group could be in part responsible for 
their conclusion that SCLE patients do not constitute a homoge-
neous, well-defined lupus subset. 
Our immunofluorescence studies support the distinctive nature 
ofSCLE, in that the pattern of direct immunofluorescence in SCLE 
was decisively different from that seen in DLE, i.e., a particulate 
epidermal pattern of staining in SCLE as opposed to the particulate 
DE] pattern in DLE. This provides independent evidence that the 
clinical segregation of cutaneous LE patients into two distinct 
groups was accurate. The IF findings in SCLE are consistent with 
past studies in animals, in which Lee, Gaither, Coulter, et al showed 
a similar pattern of particulate epidermal staining in human skin 
grafted on~o. immu~osup£ressed mice,. after injec~ion wi~h huma.n 
sera containing anti-Ro/SSA antibodies or affimty pUrIfied anti-
Ro/SSA antibodies [16]. A similar pattern of keratinocyte staining 
was induced with ultraviolet light irradiation in both cultured kera-
tinocytes and in vivo, using suction blisters [38,39]. These studies 
showed that specific anti-Ro binding occurred on the keratinocyte 
cell surfaces as well as in the cytoplasm and nucleus. The binding 
was dependent on protein synthesis, glycocylation or glycolysis, and 
microfilament production, but was not cell-cycle-phase depen-
dent. Our direct immunofluorescence studies did not allow distinc-
tions between cytoplasmic staining and cell-surface staining; thus 
we cannot be certain of the precise location of the IgG deposition. 
Because we did not see this particulate epidermal pattern of IF 
staining in DLE patients, even those with anti-Ro/SSA antibodies, 
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we believe direct IF may prove to be a useful test for SCLE. It is not 
yet clear whether the epidermal pattern of IF staining correlates 
more strongly with SCLE or with anti-Ro/SSA antibodies. First, all 
patients with SCLE had anti-Ro/SSA antibodies. Second, the DLE 
patients who had anti-Ro/SSA antibodies had relatively low levels 
of circulating anti-Ro/SSA at the time they were evaluated. It IS 
therefore possible that the explanation for the lack of epidermal ~gG 
deposits in the anti-Ro/SSA positive DLE patients is quantitatlv.e. 
The distinctive DIF staining in SCLE patients was seen not only In 
lesional skin specimens, but also in non-Iesional sun-exposed a~d 
non-lesional unexposed skin, even in patients who had no systemIC 
disease. Thus, in contrast to DLE patients, where positive DIF find-
ings in non-lesional skin often correlate with the presence of SLE, 
immunoreactants in non-Iesional skin of SCLE patients do not ne~­
essarily indicate systemic disease. Further, the widespread depOSI-
tion of antibody, including areas of uninvolved skin, is seen in other 
skin diseases where antibodies are believed to be important in pa~h­
ogenesis, e.g., pemphigus. Such findings emphasize the compleXity 
of this disease, and imply that multiple steps are necessary for the 
development of skin lesions. 
The etiology of LE and the role of autoantibodies in LE have not 
been established. Previous work using patients classified as haVIng 
DLE lesions has led to the conclusion that autoantibodies are not 
involved in the pathogenesis of cutaneous LE. However, the associa-
tion of particular autoantibodies, anti-Ro/SSA, with SCLE, and the 
appearance of transient SCLE lesions in newborns whose mothers 
have anti-Ro/SSA, has led to the re-examination of this conclUSion. 
Our work supports the hypothesis that anti-Ro/SSA antibodies are 
deposited in the skin in SCLE, because all patients had the distinc-
tive epidermal IgG pattern shown in an experimental model to be 
due to anti-Ro/SSA. It also provides indirect evidence that antibody 
deposition may precede lesion formation in SCLE. This informa-
tion supports the possibili ty that anti-Ro/SSA is an etiologic agent 
in SCLE. It should be noted that scarring discoid lesions have ~ot 
been reported in newborns. This, together with the distinctive ch~­
ical and histologic features ofSCLE and DLE and the differences In 
the location of antibody deposits in the skin in the two diseases, 
indicates that SCLE and DLE may have different etiologies. 
------------------------------------------------------
We gratefully acknowledge the statistical analysis by Major Richard ShemJalI all~ 
Melissa Damiano, the photomicrography by LTC James E. Fitzpatrick, M.D., all. 




1. Tan EM, Cohen AS, Fries JF, et al: The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis RheuJll 
25:1271-1277,1982 
2. Sontheimer RD, Thomas JR, Gilliam IN: Subacute cutaneous lupUS 
erythematosus: a cutaneous marker for a distinct lupus erythematO-
sus subset. Arch Dermatol 115: 1409 - 1415, 1979 
3. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P; 
Gilliam IN: Serologic and HLA associations of subacute cutan~un 
lupus erythematosus, a clinical subset of lupus erythematosus. n 
Intern Med 97:664-671,1982 
4. Sontheimer RD, Stastny P, Gilliam IN: Human histoCOmpatibilij 
antigen associations in subacute cutaneous lupus erythematOSus. 
Clin Invest 67:312-316,1981 
5. Bal).gertJL, Freeman RG, Sontheimer RD, GilliamJN: SubacuteCu~~ 
neou~ lupus erythematosus a~d discoid lupus erythematosuS:_c~37, 
paratlve histopathologic findings. Arch Dermatol 120:332 
1984 
s lupUS 6. Callen JP, Kulick KB, Stelzer G, Fowler JF: Subacute cutaneou d' of 
erythematosus: clinical, serologic, and immunogenetiC stU le~a_ 
forty-nine patients seen in a nonreferral setting. J Am Acad Der 
tol 15:1277 -1237, 1986 
VOL. 99, NO.3 SEPTEMBER 1992 
7. Callen JP, Klein J: Subacute cutaneous lupus erythematosus: clinical, 
serologic, immunogenetic, and therapeutic considerations in sev-
enty-two patients. Arthritis Rheum 1:1007-1013,1988 
8. Hood AF, Farmer ER: Histopathology of cutaneous lupus erythemato-
sus. In: Callen JP (ed.) . Clinics in Dermatology. JB Lippincott, 
Philadelphia, 1985, 36-48 
9. Jerdan MS, Hood AF, Moore GW, CallenJP: Histopathologic com-
parison of the subsets of lupus erythematosus. Arch Derma to I 
126:52-55,1990 
10. Nieboer C, Tak-Diamand Z, Van Leeuwen-Wallau HE: Dust-like 
particles: a specific direct immunofluorescence pattern in sub-acute 
cutaneous lupus erythematosus. Br J Dermatol 118:725 - 734, 1988 
11. McHugh NJ, Maddison PJ, MacCleod TIF, et al: Papular lesions and 
cutaneous lupus erythematosus: a comparative clinical and histologi-
cal study using monoclonal antibodies. J Rheumatol 15:1097-
1103, 1988 
12. Roujeau JC, Andre C, Bertolus S, Lemann M, Touraine R: Lupus 
cutane subaigu: etude critique. Ann Med Int 138:592-594, 1987 
13. Cripps DJ, Rankin J: Action spectra oflupus erythematosus and experi-
mental immunofluorescence. Arch Dermatol 107:563 - 567, 1973 
14. Gilliam IN, ·Sontheimer RD: Distinctive cutaneous subsets in the 
spectrum of lupus erythematosus. JAm Acad DermatoI4:471-475, 
1981 
15. Lee LA, Weston WL, Krueger GG, et al: An animal model of antibody 
binding in cutaneous lupus. Arthritis Rheum 29:782- 788, 1986 
16. Lee LA, Gaither KK, Coulter SN, Norris DA, Harley JB: Pattern of 
cutaneous immunoglobulin G deposition in subacute cutaneous 
lupus erythematosus is reproduced by infusing purified anti-Ro 
(SSA) autoantibodies into human skin-grafted mice. J Clin Invest 
83: 1556 - 1562, 1989 
17. Weston WL, Harmon C, Peebles C, et al: A serologic marker for 
neonatal lupus erythematosus. Br J Dermatol 107:377 - 382, 1982 
18. Scott JS, Maddison PJ, Taylor PV, Esscher E, Scott 0, Skinner RP: 
Connective-tissue disease, antibodies to ribonucleoprotein, and con-
genital heart block. N Engl J Med 309:209 - 212, 1983 
19. Deutscher SL, Harley JB, Keene JD: Molecular analysis of the 60-kDa 
human Ro ribonucleoprotein. Proc Natl Acad Sci USA 85:9479-
9483, 1988 
20. Ben-Chetrit E, Chan EKL, Sullivan KF, Tan EM: The 52-kD protein 
is a novel component of the SS-A/Ro antigenic particle. J Exp Med 
167:1560-1571,1988 
21. Rader MD, O'Brien C, Yunshang L, Harley JB, ReichlinM: Heteroge-
neity of the Ro/SSA antigen: different molecular forms in lympho-
cytes and red blood cells. J Clin Invest 3:1293-1298,1989 
22. McCauliffe DP, Lux FA, Lieu T-S, et al: Molecular cloning, expres-
sion, and chromosome 19 localization of a human Ro/SS-A autoan-
tigen. J Clin Invest 85:1379 -1391, 1990 
23. McCauliffe DP, Zappi E, Lieu T-S, Michalak M, Sontheimer RD, 
Capra JD: A human Ro/SS-A autoantigen is the homologue of 
calreticulin and is highly homologous with onchocercal RAL-l an-
tigen and an aplysia "memory molecule." J Clin Invest 86:332-
335,1990 
DISTINCTIONS BETWEEN SCLE AND DLE 257 
24. Lerner MR, Boyle JA, HardinJA, Steitz JA: Two novel classes of small 
ribonucleoproteins detected by antibodies associated with lupus ery-
thematosus. Science 211:400-402,1981 
25. Pettersson I, Hinterberger M, Mimori T, Gottlieb E, Steitz JA: The 
structure of mammalian small nuclear ribonucleoproteins: identifi-
cation of multiple protein components reactive with anti-(Ul)ribo-
nucleoprotein and anti-Sm autoantibodies. J Bioi Chem 259:5907-
5914,1984 
26. Chambers JC, Keene JD: Isolation and analysis of cDNA clones ex-
pressing human lupus La antigen. Proc Nat! Acad Sci USA 
82:2115 -2119, 1985 
27. Sharp PA: Splicing of messenger RNA precursors. Science 235:766-
771,1987 
28. Ruby SW, Abelson J: An early hierarchic role of Ul small nuclear 
ribonucleoprotein in spliceosome assembly. Science 242:1028-
1035,1988 
29. Gottlieb E, Steitz JA: Function of the mammalian La protein: evidence 
for its action in transcription termination by RNA polymerase III. 
EMBOJ 8:851-861 , 1989 
30. Boire G, Craft J: Biochemical and immunological heterogeneity of the 
Ro ribonucleoprotein particles: analysis with sera specific for RohYS 
particle. J Clin Invest 84:270 - 279, 1989 
31. Wolska H, Blaszczyk M, Jablonska S: Phototests in patients with 
various forms of lupus erythematosus. Int J Dermatol 28:98 - 103, 
1989 
32. Lehmann P, Holzle E, Kind P, Goerz G, Plewig G: )Experimental 
reproduction of skin lesions in lupus erythematosus by UVA and 
UVB radiation. J Am Acad Dermatol 22:181-187, 1990 
33. David KM, Thornton JC, Davis BM, Sontheimer RD, Gilliam IN: 
Morbidity and mortality in patients with subacute cutaneous lupus 
erythematosus (abstr). J Invest Dermatol 82:408 - 409, 1984 
34. Huff JC, Weston WL, Wanda KD: Enhancement of specific immuno-
fluorescent findings with use of a para-phenylenediamine mounting 
buffer. J Invest Dermatol 78:449 - 450, 1982 
35. Yamagata H, Harley JB, Reichlin M: Molecular properties of the 
Ro/SSA antigen and enzyme-linked immunosorbent assay for 
quantitation of antibody. J Clin Invest 74:625-633,1984 
36. Harley JB, Alexander EL, Bias WB, Fox OF, Provost TT, Reichlin M, 
Yamagata H, Arnett FC: Anti-Ro(SS-A) and anti-La(SS-B) in pa-
tients with Sjogren's syndrome. Arthritis Rheum 29: 196 - 206, 
1986 
37. Sontheimer RD: Subacute cutaneous lupus erythematosus: a decade's 
perspective. Med Clin North Amer 73:1073-1090, 1989 
38. LeFeber WP, Norris DA, Ryan SR, HuffJC, Lee LA, Kubo M, Boyce 
ST, Kotzin BL, Weston WL: Ultraviolet light induces binding of 
antibodies to selected nuclear antigens on cultured human keratino-
cytes. J C lin Invest 74:1545 -1551, 1984 
39. Furukawa F, Kashihara-Sawami M, Lyons MB, Norris DA: Binding of 
antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La 
is induced on the surface of human keratinocytes by ultraviolet 
(UVL): implications for the pathogenesis of photosensitive cutane-
ous lupus. J Invest Dermatol 94:77 -85, 1990 
